
François Torche
CEO, CluePoints
Discipline of Innovation
23 Years of Industry Experience
“The value of an idea lies in the using of it.” T. Edison
Discipline of Innovation
23 Years of Industry Experience
“The value of an idea lies in the using of it.” T. Edison
Fill out the form and get your free copy of the SCDM White Paper!
5 August 2022
3 June 2022
13 May 2022
1 April 2022
4 February 2022
8 July 2021
4 June 2021
7 May 2021
2 April 2021
5 March 2021
5 February 2021
15 January 2021
14 October 2019 Face to Face Meeting
November, 2018
October, 2018
September, 2018
July, 2018
March, 2018
January, 2018
Co-Founder & Chief Scientist, NNAISENSE
The New York Times headlined: “When A.I. Matures, It May Call Jürgen Schmidhuber ‘Dad.'” Since age 15 or so, his main goal has been to build a self-improving Artificial Intelligence smarter than himself, then retire. His lab’s Deep Learning Neural Networks (NNs) based on ideas published in the “Annus Mirabilis” 1990-1991 have revolutionised machine learning and AI. In 2009, the CTC-trained Long Short-Term Memory (LSTM) of his team was the first recurrent NN to win international pattern recognition competitions. In 2010, his lab’s fast and deep feedforward NNs on GPUs greatly outperformed previous methods, without using any unsupervised pre-training, a popular deep learning strategy that he pioneered in 1991. In 2011, the DanNet of his team was the first feedforward NN to win computer vision contests, achieving superhuman performance. In 2012, they had the first deep NN to win a medical imaging contest (on cancer detection). This deep learning revolution quickly spread from Europe to North America and Asia, and attracted enormous interest from industry. By the mid 2010s, his lab’s NNs were on 3 billion devices, and used billions of times per day through users of the world’s most valuable public companies, e.g., for greatly improved speech recognition on all Android smartphones, greatly improved machine translation through Google Translate and Facebook (over 4 billion LSTM-based translations per day), Apple’s Siri and Quicktype on all iPhones, the answers of Amazon’s Alexa, and numerous other applications. In May 2015, his team published the Highway Net, the first working really deep feedforward NN with hundreds of layers—its open-gated version called ResNet (Dec 2015) has become the most cited NN of the 21st century, LSTM the most cited NN of the 20th (Bloomberg called LSTM the arguably most commercial AI achievement). His lab’s NNs are now heavily used in healthcare and medicine, helping to make human lives longer and healthier. His research group also established the fields of mathematically rigorous universal AI and recursive self-improvement in metalearning machines that learn to learn (since 1987). In 1990, he introduced unsupervised generative adversarial neural networks that fight each other in a minimax game to implement artificial curiosity (the famous GANs are instances thereof). In 1991, he introduced neural fast weight programmers formally equivalent to what’s now called linear Transformers (popular in natural language processing). His formal theory of creativity & curiosity & fun explains art, science, music, and humor. He also generalized algorithmic information theory and the many-worlds theory of physics, and introduced the concept of Low-Complexity Art, the information age’s extreme form of minimal art. He is recipient of numerous awards, author of about 400 peer-reviewed papers, and Chief Scientist of the company NNAISENSE, which aims at building the first practical general purpose AI. He is a frequent keynote speaker, and advising various governments on AI strategies.
Davide Gaudesi is an accomplished Clinical Data Manager, data passionate, database programmer and digital solutions explorer. Working as a Clinical Data Manager supporting physicians of his University (University of Milano-Bicocca (ITALY)) and his customers, he can pursue the passion for data management, facing new challenges, learning new skills and becoming the best version of himself.
Through social media, Davide shares his vision about Clinical Data Management with all his community and he contributed actively to the growth of the Society for Clinical Data Management as an active member of the Academic Committee, the EMEA steering committee and as a reviewer of the newborn Journal of the Society of Clinical Data Management.
Before dedicating his life to Clinical Data Management, Davide accomplished a successful academic career for 15 years publishing 13 papers in peer-reviewed journals.
Irina has been part of the Bioforum team for seven years and manager of the Data Management Department for three years. She is responsible for leading and overseeing all data management personnel as well as directing and guiding the data management activities of the company.
Irina develops and implements strategies and policies for data management that maximize the quality, reliability, and efficiency of deliverables while also ensuring client requirements are met and the industry performs its best practices.
Tanya is currently Chief Data Strategist & Solutions Officer at Bioforum, she has 17 years of experience in the industry. Throughout her career, Tanya has worked with multinational pharmaceutical companies as well as small-to-mid size biotechs and startups.
She has led various data management operations and programs, heading numerous innovation teams and spearheading the development of strategies for customized data delivery solutions, focusing on timely, quality data. Tanya is also a certified clinical data manager (CCDM, SCDM) as well as a project management professional (certified PMP).
Committee Chair: Susan Howard
Board Liaison: Meredith Zozus
The Content Alignment Committee is composed of two members from each of the GCDMP©, Certification, and Education Committees and members of the Board. The committee is responsible for increasing alignment between these three key SCDM offerings.
While it would be presumptuous to attempt to predict what 2030 is about, there are clear signals that it would be vastly different than today. The changes in clinical research approaches, the rapid advances in technologies and the generalization of risk-based approaches endorsed by regulators have all started to reshape our discipline. Some organizations have already successfully embarked into the Artificial Intelligence journey and expect to release data review tools powered by Machine Learning in 2021 (i.e., TOMORROW!). If it was not enough, COVID-19 has added fuel to the fire by accelerating the decentralization of clinical trials. This trend is global and EMEA cannot dodge the bullet. There is no going back, we have past the inflection point leading us toward an exciting but different future. Join the SCDM Innovation Committee Chair if you want to better understand what is looming in front of us.
This topic will focus on Risk Based Management from a variety of angles including the quality of the data produced.
Submissions should focus on matters related to risk-based approaches and how they impact CDM:
– RBM’s impact on CDM and visa versa
– Risk-based CDM approach
– QMP management
– QMP with source diversification
This topic should cover the methods of handling the collaboration between customer and clinical data management (i.e. CDM and clinical trial teams, CDM and sites, CMD and CRAs, CDM and subjects, etc.).
This topic will focus on Risk Based Management from a variety of angles including the quality of the data produced.
This topic should cover how CDM organization behaves with respect to the CDM community, what are the potential improvements we should work on in the future, what are the lessons learned from past experiences, etc.
This topic should cover real approaches on new technological and innovation approaches not covered in previous topic and/ or coming not necessarily from CDM (e.g. public health management, finance, physics, etc).
This topic should focus on real cases showing how academia/ Academic Research Organizations (ARO), CRO and pharma are handling data integrity for eSource, adaptive trial design, how they can assure quality by design, what are their perspectives about actual and potential consequences on CDM, how role & responsibilities are changing and will change in the transformation from CDM to Clinical Data Scientist, what will be the relationship with ‘other’ groups (ClinOps, medics, etc.).
This topic should cover real procedures on Data Management best practices and metrics for different data sources (wearables, apps, sensors, Big Data), application of ML/AI/Bots/Big Data Challenge in data analysis, Computer System Validation processes for home-grown applications/functionalities, new study designs, use of Real-world data in clinical development.
08:00 AM – 08:10 AM | Introduction to SCDM Mayank Anand Head Global Data Management Service Delivery for Global Clinical Operations, Bristol Myers Squibb (BMS), Member, Board of Trustees SCDM |
|
08:10 AM – 08:20 AM | Introduction to First Virtual Single Day Event Shobhit Shrotriya Life Sciences R&D Operations,Accenture, SCDM India Steering Committee Chairperson |
|
08:20 AM – 09:00 AM | Keynote Speaker 1 Concept of Virtual Trials in the Current Digital Era Craig Lipset Advisor & Founder, Clinical Innovation Partners |
|
09:00 AM – 09:40 AM | Keynote Speaker 2 Virtuals Trials and the Current Covid Situation Kent Thoelke EVP and Chief Scientific Officer, PRA Health Sciences |
|
09:40 AM – 10:20 AM | Keynote Speaker 3 Virtual trials from a Technology Perspective with Case Studies Michael Tucker Senior mHealth Product Specialist, Medidata Solutions |
|
10:20 AM – 10:45 AM | Break | |
10:45 AM – 11:30 AM | Panel Discussion Reimagining Clinical Research – Enhancing the ‘Patient Centricity’ through Decentralized Clinical Trials |
|
11:30 AM – 12:00 PM | Platinum Sponsor Presentation Oracle Health Sciences |
|
12:00 PM – 01:00 PM | Lunch Break | |
01:00 PM – 02:30 PM | Industry Workshop 1 Medidata Solutions Virtual Trial Technologies to improve patient enrollment, retention, and engagement |
|
02:30 PM – 03:00 PM | Break | |
03:00 PM – 04:30 PM | Industry Workshop 2 Veeva Systems Technologies that improve site, Sponsor and CRO execution of studies, and how can they address global challenges, like COVID-19 |
|
04:30 PM – 04:45 PM | Vote of Thanks Mayank Anand Head Global Data Management Service Delivery for Global Clinical Operations, Bristol Myers Squibb (BMS), Member, Board of Trustees SCDMShobhit Shrotriya Life Sciences R&D Operations,Accenture, SCDM India Steering Committee Chairperson |
Facilitator: Shobhit Shrotriya
Vice President, Clinical & Regulatory Services,
Accenture Applied Life Sciences Solutions
Reimagining Clinical Research – Enhancing the ‘Patient Centricity’ through Decentralized Clinical Trials
The world post Covid-19 will be different and continue to evolve in a dynamic fashion. Changes to the way clinical research is conducted today is certainly imminent. As one can imagine, the innovations in clinical research would happen now more than ever. During this panel discussion, we will discuss how decentralized clinical trials (DCTs) offer a more patient-centric approach with fewer visits to the clinic, thereby reducing the burden on investigator, patient and health caregiver. During this changing time, the critical imperatives of DCTs would be to focus on patient safety, ensure data quality and maintain research continuity seamlessly.
Key themes:
Fill out the form and get your free copy of the SCDM White Paper!
Fill out the form and get your free copy of the GCDMP©!